Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Abatacept Appears Safe for RA Patients with COPD

Key clinical point: Abatacept doesn’t appear to exacerbate COPD in patients with rheumatoid arthritis.

Major finding: Risks for COPD exacerbation, flu, bronchitis, and pneumonia were not significantly elevated versus those with other biologic DMARDs.

Study details: The MarketScan database review comprised 4,634 patients.

Disclosures: Dr. Suissa disclosed relationships with AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, and Novartis.

Citation:

Suissa S et al. Semin Arthritis Rheum. 2019 Mar 16. doi: 10.1016j.semarthrit.2019.03.007.